Sequence Bio
Discovering the true signals of disease to power life-changing drugs.
What they do
Most drug candidates fail because disease signals and drug targets are poorly understood, leading to wasted R&D and delayed treatments.
It uses population genetics and data from the Newfoundland founder population to identify and validate better drug targets for pharma R&D.
Pharmaceutical and biotechnology companies and their drug discovery/R&D teams.
Founders
Ph.D. in Molecular Genetics and Cell Biology (University of Chicago, 2000); J.D. with Honors (University of Chicago Law School, 2003). Previously: CBO, Sequence Bio S19 (Raised >$10m; LOIs signed with Sema4, Helix and Biogen); EVP, Strategic Development, Antibe Therapeutics (International partnerships, public company financings and disclosures; preclinical through Phase 1 for a novel pain therapeutic) Best dog dad ever; 7 out of 10 human dad.
Company timeline
- Founded2013
- YC batchSummer 2019
- StatusActive
- Team size52 people
- LocationSt. John's, NL, Canada
Similar startups
